Xiao Lin

机构：Wenzhou Medical University, Ruian People's Hospital · ORCID：0000-0003-0478-3244

发表论文 33 篇 · 总被引 704 次 · h-index 11

代表论文

• Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer (2021 · JAMA Oncology · 被引 405)
• HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma (2022 · Future Oncology · 被引 64)
• Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial (2024 · ESMO Open · 被引 44)
• The economic burden and quality of life of patients with psoriasis treated with biologics in China (2023 · Journal of Dermatological Treatment · 被引 16)
• MiR-30a sensitized lung cancer against neoadjuvant chemotherapy by depressing autophagy (2021 · Japanese Journal of Clinical Oncology · 被引 16)
• Prognostic Value of the Modified Systemic Inflammation Score in Patients With Extranodal Natural Killer/T-Cell Lymphoma (2020 · Frontiers in Pharmacology · 被引 14)